novo-venture-companies-25.html
Novo Annual Report 2015
26 / 72
2015
was another great liquidity year for novo?s private portfolio
companies
. during the year, we saw one company acquired by novartis and four private portfolio companies become publicly traded companies on nasdaq in the us. 2015 public crop ? adaptimmune (adap) ? colucid pharmaceuticals (clcd) ? htg molecular diagnostics (htgm) ? tobira therapeutics (tbra) a busy public year early may 2015 was a particular busy time for us. in just three days, four of novo?s portfolio companies became publicly traded companies. tobira therapeutics merged with regado biosciences on 5 may; colucid pharmaceuticals and htg molecular completed their initial offerings on 6 may; and adaptimmune went public on nasdaq on 7 may. m&as and ipos in 2015 switzerland france finland denmark uk usa number of successful exits per country invested 1 1 1 3 4 29 switzerland france finland canada sweden uk denmark usa number of all exits per country 1 1 1 1 1 7 16 45 2015 was another great liquidity year for novo?s private portfolio companies. spinifex was sold to novartis for usd 200 million and four private portfolio companies went public on nasdaq. novo a/s 26 novo ventures
pain-neuropathic-spinifex-27.html
